- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03169478
Intrauterine Balloon Dilatation Therapy in the Prevention of Adhesion Formation After Hysteroscopic Myomectomy
The Efficacy of Intrauterine Balloon Dilatation Therapy in the Prevention of Adhesion Formation After Hysteroscopicremovalof Multiple Fibroids
Transcervical resection of submucous myomas (TCRM) is nowadays considered necessary if it is associated with infertility or miscarriage or menorrhagia. Nevertheless, one possible risk of hysteroscopic myomectomy is the formation of intrauterine adhesion (IUA) at the site of resection. The development of IUA arising from trauma to the basalis layer of the endometrium during hysteroscopy can result in infertility, recurrent miscarriages, amenorrhea, dysmenorrhea, or abnormal placentation.
Several measures have been proposed in an effort to decrease the formation of post-surgical intrauterine adhesions. Additionally, physical barriers such as balloon catheters or intrauterine devices have been used in the postoperative period. Despite years of studies evaluating prevention strategies for intrauterine adhesion formation after operative hysteroscopy, it is still unclear which strategy is most effective because there has never been any formal properly powered randomized, control trial to examine the efficacy of the various methods used to prevent adhesion reformation.
In this prospective, randomized, controlled study, the investigators wish to examine the efficacy of intrauterine balloon dilatation therapy in the early postoperative period in preventing adhesion formation after transcervical resection of submucous myomas.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Objectives
To investigate the efficacy of intrauterine balloon (IUB) dilatation therapy in the prevention of adhesion formation after transcervical resection of submucous myomas (TCRM).
Patients
The patients will be recruited from two centers, namely, the Hysterscopy Center of the Fuxing Hospital and TianTan Hospital, Capital Medical University, Beijing, China. Before the surgery all patients with suspected submucous myomas will undergo preoperative evaluations including trans-vaginal ultrasonography. The inclusion criteria include [1] women aged 18-45 years with regular 25-35 days cycles ; [2] no evidence of intrauterine adhesions at the time of surgery; [3] written consent obtained; and [4] agreement to have second-look hysteroscopy; [5] had more than one fibroids removed at the time of hysteroscopic surgery. The exclusion criteria include women who are already postmenopausal or women who have evidence of intrauterine adhesions at the time of surgery.
Study Design
After the completion of transcervical resection of submucous myomas (TCRM), recruited patients will be randomized to one of the two treatment groups by computer-generated numbers: [1] study group will have Foley-catheter intrauterine balloon dilatation therapy 2 weeks and 4 weeks after hysteroscopic myomectomy; [2] the control group will not receiveany balloon therapy. A second-look hysteroscopy will be carried out around 6 weeks after the surgery.
Procedure
Surgical procedure
The surgery will be carried out by an experienced hysteroscopic surgeons with the use of a 8.5 mm rigid hysteroscope with under 100-120 mm Hg pressure. The procedure will be performed under general anesthesia in a day surgery unit under ultrasonographic guidance. Once the type and number of myomas have been verified, the myoma will be then be bluntly dissected from the muscular layer with the tip of the resectoscope. After the myomas have been dissected from the muscular layer, they will be shaved into pieces to reduce the volume and then be retrieved from the uterine cavity with a myoma grasper.
Postoperative treatments
All patients will be treated with oral antibiotics for 3-5 days in line with local practice. Second-look hysteroscopy will be carried out 6 weeks after the initial operation. After assessment of the extent and severity of any newly formed adhesion, hysteroscopic adhesiolysis, if needed, will be carried out at the time of the second-look procedure. Immediately prior to second look hysteroscopy, a swab will be taken from the endo-cervical canal for routine bacteriological study; At the conclusion of the second look hysteroscopy, an endometrial sample will be obtained for histological study &immune histochemical analysis including evidence of chronic endometrtitis(CD138 staining). The surgeons who perform the second-look will be blinded to the randomization.
IUB dilatation therapy
IUB dilatation therapy will be performed according to the methodology published in the literature. In brief, a Foley catheter (size 12-14fr) will be prepared by cutting the excess catheter tip protruding beyond the balloon. Once the catheter has reached the fundus, 3-5mls of saline will be slowly introduced into the balloon under ultrasound guidance, in order to directly visualize the distention of the cavity and stretching and blunt dissection of any intrauterine adhesions, if present.
Statistical Analysis
The efficacy of treating the intrauterine adhesions in the two groups will be compared using the χ2 test. The AFS score in the two groups will be compared using the Mann-Whitney U test. A p value of < 0.05 will be considered statistically significant. All statistical analysis will be carried out with the use of SPSS 21.0.
Power calculation
On the basis of the investigators own internal audit and the results of the two published retrospective cohort studies analysing the prevalence of intrauterine adhesion (IUA) formation in women undergoing transcervical resection of multiple submucousmyomas (TCRM),the investigators estimated that the adhesion formation rate in the control group to be 25% and the treatment group (balloon group) to be 5%; accepting a type 1 error of 0.05, and a type 2 error of 0.10, the number of subjects required in each arm of the randomized controlled trial would be 51. Assuming that the drop-out rate to be 10%, the total number of subject to be recruited would be 56 in each arm, that is a total of 112.
Outcome measures
The primary outcome measure will be the amount of intrauterine adhesions as measured according to the AFS score at follow-up. The secondary outcome measures will include any complications including any clinical infection and change of menstrual pattern after surgery and the need for re-operation.
Data processing and analysis
The researchers will ensure the confidentiality of sensitive data by minimizing the number of personnel who handle subject data. In addition, computer data will be encrypted as required to maximize security, while paper documents will be locked in filing cabinets, with only authorized personnel having access to the information.
Ethical considerations
IUB dilatation has been published as a novel technique with no untoward complications identified to date. The procedure will be performed according to the methodology available in the literature and the study has gained approval from the local ethical committee (Approval Notice Number:2016FXHEC-KY005).
Consent
All subjects will be given a detailed explanation of the study and sufficient time to consider participants. A written consent form will be signed by the patient and retained in the investigators confidential records.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Lei Guo
- Phone Number: +86 15810635320
- Email: guolei.yale@163.com
Study Contact Backup
- Name: Tinchiu Li
- Phone Number: +86 010 88062944
- Email: tinchiu.li@gmail.com
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100038
- Recruiting
- Fu Xing Hospital
-
Contact:
- Lei Guo
- Phone Number: +86 010-88062291
- Email: guolei.yale@163.com
-
Contact:
- Tinchiu Li, Ph.D.
- Email: tinchiuli@gmail.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- [1] women aged 18-45 years with regular 25-35 days cycles ;
- [2] no evidence of intrauterine adhesions at the time of surgery;
- [3] written consent obtained;
- [4] agreement to have second-look hysteroscopy;
- [5] had more than one fibroids removed at the time of hysteroscopic surgery
Exclusion Criteria:
- [1] women who are already postmenopausal
- [2] women who have evidence of intrauterine adhesions at the time of surgeryare
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
No Intervention: multiple myoma control group
The control group will not have any balloon therapy.
A second-look hysteroscopy will be carried out 6 weeks after the surgery.
|
|
Experimental: multiple myoma IUB dilatation group
The multiple myoma study group will have Foley-catheter intrauterine balloon dilatation therapy 2 weeks and 4 weeks after hysteroscopic myomectomy.
A second-look hysteroscopy will be carried out 6 weeks after the surgery.
|
A Foley catheter (size 8-12fr) will be prepared by cutting the excess catheter tip protruding beyond the balloon.
Once the catheter has reached the fundus, 3-5mls of saline will be slowly introduced into the balloon under ultrasound guidance, in order to directly visualize the distention of the cavity and stretching and blunt dissection of any intrauterine adhesions, if present.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The amount of intrauterine adhesions at second look hysteroscopy
Time Frame: at 6 weeks post-op
|
The amount of intrauterine adhesions according to AFS score at second look hysteroscopy
|
at 6 weeks post-op
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
complications of hysteroscopic myomectomy
Time Frame: at 6 weeks post-op
|
complications of hysteroscopic myomectomy including infection rate
|
at 6 weeks post-op
|
menstrual pattern
Time Frame: at 3 months post-op
|
The menstrual pattern before and after surgery and the need for re-operation
|
at 3 months post-op
|
Collaborators and Investigators
Collaborators
Investigators
- Study Chair: Tinchiu Li, Fu Xing Hospital, Capital Medical University
Publications and helpful links
General Publications
- Orhue AA, Aziken ME, Igbefoh JO. A comparison of two adjunctive treatments for intrauterine adhesions following lysis. Int J Gynaecol Obstet. 2003 Jul;82(1):49-56. doi: 10.1016/s0020-7292(03)00030-4.
- Guida M, Acunzo G, Di Spiezio Sardo A, Bifulco G, Piccoli R, Pellicano M, Cerrota G, Cirillo D, Nappi C. Effectiveness of auto-crosslinked hyaluronic acid gel in the prevention of intrauterine adhesions after hysteroscopic surgery: a prospective, randomized, controlled study. Hum Reprod. 2004 Jun;19(6):1461-4. doi: 10.1093/humrep/deh238. Epub 2004 Apr 22.
- Saravelos SH, Li TC. Ultrasound-guided treatment of intrauterine adhesions in the outpatient setting. Ultrasound Obstet Gynecol. 2017 Aug;50(2):278-280. doi: 10.1002/uog.16218. No abstract available.
- Saravelos SH and Li TC. Intrauterine balloon therapy: a novel ultrasound guided treatment for intrauterine adhesions. Gynecological Surgery [Epub ahead of print]
- Saravelos SH, Jayaprakasan K, Ojha K, Li TC. Assessment of the uterus with three-dimensional ultrasound in women undergoing ART. Hum Reprod Update. 2017 Mar 1;23(2):188-210. doi: 10.1093/humupd/dmw040.
- Taskin O, Sadik S, Onoglu A, Gokdeniz R, Erturan E, Burak F, Wheeler JM. Role of endometrial suppression on the frequency of intrauterine adhesions after resectoscopic surgery. J Am Assoc Gynecol Laparosc. 2000 Aug;7(3):351-4. doi: 10.1016/s1074-3804(05)60478-1.
- Healy MW, Schexnayder B, Connell MT, Terry N, DeCherney AH, Csokmay JM, Yauger BJ, Hill MJ. Intrauterine adhesion prevention after hysteroscopy: a systematic review and meta-analysis. Am J Obstet Gynecol. 2016 Sep;215(3):267-275.e7. doi: 10.1016/j.ajog.2016.05.001. Epub 2016 May 10.
- Roge P, D'Ercole C, Cravello L, Boubli L, Blanc B. Hysteroscopic management of uterine synechiae: a series of 102 observations. Eur J Obstet Gynecol Reprod Biol. 1996 Apr;65(2):189-93. doi: 10.1016/0301-2115(95)02342-9.
- Schenker JG. Etiology of and therapeutic approach to synechia uteri. Eur J Obstet Gynecol Reprod Biol. 1996 Mar;65(1):109-13. doi: 10.1016/0028-2243(95)02315-j.
- Pabuccu R, Atay V, Orhon E, Urman B, Ergun A. Hysteroscopic treatment of intrauterine adhesions is safe and effective in the restoration of normal menstruation and fertility. Fertil Steril. 1997 Dec;68(6):1141-3. doi: 10.1016/s0015-0282(97)00375-0.
- March CM. Intrauterine adhesions. Obstet Gynecol Clin North Am. 1995 Sep;22(3):491-505.
- Varasteh NN, Neuwirth RS, Levin B, Keltz MD. Pregnancy rates after hysteroscopic polypectomy and myomectomy in infertile women. Obstet Gynecol. 1999 Aug;94(2):168-71. doi: 10.1016/s0029-7844(99)00278-1.
- Yang JH, Chen MJ, Wu MY, Chao KH, Ho HN, Yang YS. Office hysteroscopic early lysis of intrauterine adhesion after transcervical resection of multiple apposing submucous myomas. Fertil Steril. 2008 May;89(5):1254-1259. doi: 10.1016/j.fertnstert.2007.05.027. Epub 2007 Aug 8.
- Touboul C, Fernandez H, Deffieux X, Berry R, Frydman R, Gervaise A. Uterine synechiae after bipolar hysteroscopic resection of submucosal myomas in patients with infertility. Fertil Steril. 2009 Nov;92(5):1690-3. doi: 10.1016/j.fertnstert.2008.08.108. Epub 2008 Oct 19.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2017FXHEC-KY005
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Intrauterine Adhesion
-
Hua DuanRecruitingIntrauterine Adhesion | Database for Intrauterine Adhesion | Risk Factors for Intrauterine Adhesion | Risk Stratification and Prognostic AssessmentChina
-
The Fourth Affiliated Hospital of Zhejiang University...Recruiting
-
Rejoni Inc.CompletedIntrauterine AdhesionUnited States
-
Ain Shams Maternity HospitalCompletedIntrauterine AdhesionEgypt
-
Fu Xing Hospital, Capital Medical UniversityBeijing Tiantan HospitalUnknown
-
Lili CaoRecruitingScar | Intrauterine AdhesionChina
-
Nadezhda Women's Health HospitalRecruitingIntrauterine AdhesionBulgaria
-
Fu Xing Hospital, Capital Medical UniversityCompleted
-
First Affiliated Hospital, Sun Yat-Sen UniversityCompletedIntrauterine AdhesionChina
-
Xiaozheng ShuCompletedIntrauterine AdhesionChina
Clinical Trials on multiple myoma IUB dilatation group
-
Fu Xing Hospital, Capital Medical UniversityCompleted
-
PfizerCompletedColitis, UlcerativeSpain, Belgium, Germany, Czech Republic, Norway, Denmark, Slovakia
-
NYU Silver School of Social WorkCompleted
-
J2H BiotechCompletedNon-alcoholic SteatohepatitisKorea, Republic of
-
Washington University School of MedicineNational Institute of Mental Health (NIMH)Completed
-
Bridge Biotherapeutics, Inc.KCRN Research, LLCCompletedIdiopathic Pulmonary FibrosisUnited States
-
Newsoara Biopharma Co., Ltd.RecruitingT2DM (Type 2 Diabetes Mellitus)China
-
Icahn School of Medicine at Mount SinaiNational Institute of Mental Health (NIMH)CompletedConduct Disorder | Oppositional Defiant DisorderUnited States
-
Xi'an Xintong Pharmaceutical Research Co.,Ltd.RecruitingChronic Hepatitis bChina
-
Istanbul Medipol University HospitalCompletedPain, Postoperative | Endodontically Treated Teeth